Daiwa Securities Group
TERN

Daiwa Securities Group’s Terns Pharmaceuticals TERN Stock Holding History

Daiwa Securities Group’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-260
Closed -$11K – 1421
2025
Q4 		$11K Buy
260
+109
+72% +$2.52K ﹤0.01% 1183
2025
Q3 		$1K Hold
151
– – ﹤0.01% 1321
2025
Q2 		$1K Hold
151
– – ﹤0.01% 1284
2025
Q1 		$0 Hold
151
– – ﹤0.01% 1316
2024
Q4 		$1K Hold
151
– – ﹤0.01% 1269
2024
Q3 		$1K Hold
151
– – ﹤0.01% 1259
2024
Q2 		$1K Hold
151
– – ﹤0.01% 1300
2024
Q1 		$1K Hold
151
– – ﹤0.01% 1305
2023
Q4 		$1K Hold
151
– – ﹤0.01% 1309
2023
Q3 		$1K Hold
151
– – ﹤0.01% 1277
2023
Q2 		$1K Hold
151
– – ﹤0.01% 1300
2023
Q1 		$2K Hold
151
– – ﹤0.01% 1228
2022
Q4 		$2K Buy
+151
New +$1K ﹤0.01% 1242

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Daiwa Securities Group's TERN Position: Q1 2026 in Review

Daiwa Securities Group sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 260 shares — an estimated $11K sold.

Daiwa Securities Group first reported a position in TERN in Q4 2022 and held it in 13 quarters. The position peaked at $11K in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Daiwa Securities Group reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 260 Terns Pharmaceuticals shares in Q1 2026, an estimated $11K.
  • Daiwa Securities Group first reported a position in Terns Pharmaceuticals in Q4 2022 and held it in 13 quarters.
  • Daiwa Securities Group's Terns Pharmaceuticals position peaked at $11K in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.